Evidence map›Paper›PMID 26381779›Full record

ArticleThe AAPS journal2016

Thermosensitive Hydrogel Co-loaded with Gold Nanoparticles and Doxorubicin for Effective Chemoradiotherapy.

Tingting Li, Mingfu Zhang, Jianzhen Wang, Tianqi Wang, Yao Yao, Xiaomei Zhang, Cai Zhang, Na Zhang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The AAPS journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. bioRxiv : the preprint server for biology · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Tingting LiDepartment of Pharmaceutics, School of Pharmaceutical Science, Shandong University, Jinan, 250012, China.
Mingfu ZhangKey Lab of Colloid and Interface Chemistry, Ministry of Education, Department of Chemistry and Chemical Engineering, Shandong University, Jinan, 250199, China.
Jianzhen WangDepartment of Radiation, Qilu Hospital of Shandong University, Jinan, 250012, China.
Tianqi WangDepartment of Pharmaceutics, School of Pharmaceutical Science, Shandong University, Jinan, 250012, China.
Yao YaoDepartment of Pharmaceutics, School of Pharmaceutical Science, Shandong University, Jinan, 250012, China.
Xiaomei ZhangDepartment of Radiation, Qilu Hospital of Shandong University, Jinan, 250012, China.
Cai ZhangInstitute of Immunopharmacology & Immunotherapy, School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China.
Na ZhangDepartment of Pharmaceutics, School of Pharmaceutical Science, Shandong University, Jinan, 250012, China. zhangnancy9@sdu.edu.cn.
Shandong University · CNQilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemoradiotherapy, as a well-established paradigm to treat various cancers, still calls for novel strategies. Recently, gold nanoparticles (AuNPs) have been shown to play an important role as a radiosensitizer in cancer radiotherapy. The aim of this study was to evaluate the combination of polyethylene glycol (PEG) modified AuNPs and doxorubicin (DOX) to improve cancer chemoradiotherapy, in which the AuNPs was the radiosensitizer and the DOX was the model chemotherapeutic. A Pluronic® F127-based thermosensitive hydrogel (Au-DOX-Gel) loading AuNPs and DOX was developed by "cold method" for intratumoral injection. The formulation was optimized at a F127 concentration of 22% for Au-DOX-Gel. The release profiles compared to a control group were assessed in vitro and in vivo. Au-DOX-Gel showed sustained release of AuNPs and DOX. The cell viability and surviving fraction of mouse melanoma (B16) and Human hepatocellular liver carcinoma (HepG2) cells were significantly inhibited by the combination treatment of DOX and AuNPs under radiation. Tumor sizes of mice were significantly decreased by Au-DOX-Gel compared to controls. Interestingly, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and Ki-67 staining results showed that tumor cell growth and proliferation were inhibited by AuNPs combined with DOX under radiation, suggesting that the radiosensitization activity and combination effects might be caused by inhibition of tumor cell growth and proliferation. Furthermore, the results of skin safety tests, histological observation of organs, and the body weight changes indicated in vivo safety of Au-DOX-Gel. In conclusion, the Au-DOX-Gel developed in this study could represent a promising strategy for improved cancer chemoradiotherapy.

Indexed as

AnimalsAntibiotics, AntineoplasticBody WeightCell Line, TumorCell ProliferationCell SurvivalDoxorubicinGoldHumansHydrogelsMelanoma, ExperimentalMetal NanoparticlesMicePoloxamerRadiation-Sensitizing AgentsRatsAntibiotics, AntineoplasticDoxorubicinGoldHydrogelsPoloxamerRadiation-Sensitizing Agentschemoradiotherapydoxorubicingold nanoparticlesthermosensitive hydrogel

Identifiers

PMID26381779
PMCPMC4706291
OpenAlexW1743607426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.